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Pseudo-Mannosylated DC-SIGN 
Ligands as Immunomodulants
Angela Berzi1,*, Stefania Ordanini2,*, Ben Joosten3, Daria Trabattoni1, Alessandra Cambi3, 
Anna Bernardi2 & Mario Clerici4,5
DC-SIGN, a C-type lectin mainly expressed by DCs, mediates antigen uptake and can induce specific 
immune responses, depending on the ligand involved. Owing to these properties, DC-SIGN is an 
attracting target for approaches aimed at tailoring the immune response towards specific immunologic 
outcomes. A multivalent DC-SIGN ligand (Polyman26), containing at its core a fluorescent “rod-
like” spacer and able to inhibit DC-SIGN mediated HIV infection in nanomolar concentration, has 
been recently developed by our group. We investigated the internalization pattern and the ability 
of Polyman26 to elicit innate immune responses. Results obtained by confocal microscopy indicate 
that Polyman26 is internalized by DCs via receptor- mediated endocytosis and is then routed to 
endolysosomal compartments, thus being presented together with MHC class II molecules, with 
important implications for the development of vaccines. Moreover, Polyman26 up-regulated the 
production of β-chemokines and pro-inflammatory cytokines (including IL-1β, IL-6, IL-12, and TNFα) 
as well as the expression of TLR9 and CD40L. These results indicate that glycomimetic DC-SIGN ligands 
should be further investigated and suggest that these compounds could be used to differentially 
stimulate immune responses.
Immunomodulatory strategies are currently used in the attempt to prevent and treat a range of pathologies, 
including viral and bacterial infection, autoimmune disorders, and cancer; these strategies, nevertheless, are still 
in a pioneering stage and need to be much better defined. Vaccination can be regarded as a form of immunomod-
ulation1,2, but whether inactivated and live attenuated vaccines have intrinsic immune stimulating properties, 
vaccines based on recombinant antigens are scarcely immunogenic and require adjuvants to properly activate 
antigen specific immune responses3,4. Studies performed over the past 20 years highlighted the crucial role of the 
innate immune system in activating, modulating, and polarizing adaptive immunity. Results led to the suggestion 
that agonists of Pattern Recognition Receptors (PRRs) could be used to stimulate immune response in chronic 
viral and bacterial infections. Notably, some of such compounds are already in clinical use (i.e. imiquimod, as a 
topical treatment for Human Papilloma Virus infection) or are in advanced stages of development. In addition, 
PRR agonists are used as adjuvants in vaccines licensed or under clinical development2,5.
Among PRRs, C-type lectin receptors (CLRs) are promising targets for shaping immune responses6. Within 
the CLR family, DC-SIGN (Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin), 
a receptor expressed by myeloid Dendritic Cell (DCs) and subpopulations of macrophages, recognizes specific 
carbohydrate structures (high mannose or fucose) on the surface of pathogens and self-glycoproteins. Upon 
ligand binding, DC-SIGN mediates endocytosis in endolysosomal compartments and antigen presentation via 
Major Histocompatibility Complex class I (MHC-I) and class II (MHC-II) molecules. The function of DC-SIGN 
can nevertheless be usurped by several pathogens, including HIV, that can exploit DC-SIGN to promote infection7,8. 
Indeed, DC-SIGN antagonists have been proposed for use as prophylactic antiviral agents and shown to inhibit 
DC-SIGN mediated infections in various in vitro and ex vivo models (for a review: ref. 9). Notably, different DC-SIGN 
ligands are known to induce distinct intracellular signaling pathways and immunological outcomes, supporting an 
important role for DC-SIGN as a target for immunomodulatory approaches10–13. Finally, thanks to its antigen uptake 
and signaling properties, DC-SIGN is a promising candidate for the development of vaccines targeting DCs14,15.
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Synthetic carbohydrate ligands, designed to interact with DC-SIGN Carbohydrate Recognition Domain 
(CRD), can be used to specifically target antigens to DCs and to modulate the host’s immune response. The mul-
tivalent presentation of synthetic glycomimetic ligands on polymeric and protein scaffolds was shown to consid-
erably increase the strength of the bond to DC-SIGN through avidity effects, and to cluster specific receptors on 
cell membrane, resulting in the elicitation of signal transduction pathways16,17. Similarly, multivalent dendrimers 
bearing glycomimetic DC-SIGN ligands performed as efficient inhibitors of DC-SIGN-mediated HIV infection 
of cellular and cervical explant models by competing with the ability of the virus to bind to the receptor18–20. 
One of the these molecules (Polyman19) could also induce the expression of β -chemokines, cytokines, and 
co-stimulatory molecules involved in activating DCs, in modulating adaptive immunity, and in counteracting 
HIV infection21.
Recently, we developed a novel type of glycodendrimers that include a linear rigid spacer (“rod-like” 
spacer) at their core22. This structure allows to control the size of the dendrimers and tune it to fit the distance 
between adjacent binding sites on a DC-SIGN tetramer, thus reaching unprecedented affinity for constructs of 
similar valency. Some of these molecules, appropriately loaded with DC-SIGN selective ligands, were shown 
to inhibit DC-SIGN-mediated HIV infection in nanomolar concentrations23. In the present work, compound 
3.5.4 (Polyman26), the most active dendrimer in this class, was further characterized. In particular, the ability 
of Polyman26 to enhance and modulate innate immune responses was evaluated with the aim of developing 
glycomimetic ligands of DC-SIGN as immunomodulators and vaccine adjuvants. Thanks to the natural fluores-
cence of the rod-like spacer, the internalization pathway and the endocytic routing of the dendrimer to specific 
sub-cellular organelles were also investigated.
Results indicate that Polyman26 modulates multiple innate responses and is internalized by DCs into the 
endolysosomal compartment. These results suggest that pseudo-mannosylated DC-SIGN ligands should be fur-
ther developed for immunomodulatory and vaccine approaches.
Results
Characterization of Fluorescence properties of Polyman26. The rod-like spacer included at the 
core of Polyman 26 (Fig. 1) is intrinsically fluorescent; hence, it can be used as a tracer in imaging studies. To 
determine the optimal setting for the experiments of fluorescence and confocal microscopy, the excitation and 
emission spectra of Polyman26 were recorded at different pH (see Supplementary info). Results showed that 
irradiation at 372 nm results in a clear emission spectrum with a main peak at 425 nm and a broader shoulder 
at 450–460 nm (Supplementary Fig. S1), producing a readable signal also at pH compatible with acidic cellu-
lar compartments (Supplementary Fig. S2). Imaging studies were performed next to analyse the interaction of 
Polyman26 with different DC-SIGN domains and the ensuing internalization of the ligand.
Binding between Polyman26 and DC-SIGN subdomains. To determine which subdomain of 
DC-SIGN is targeted by Polyman26, its binding with DC-SIGN mutants lacking specific regions was evaluated. 
To this purpose, CHO cells expressing DC-SIGN wild type (DC-SIGN-wt), DC-SIGN lacking the CRD (carbo-
hydrate recognition domain) (DC-SIGN-Δ CRD), and DC-SIGN lacking the tandem repeats in the extracellular 
neck region (DC-SIGN-Δ Rep) were obtained by transfection, whose efficiency was confirmed by Flow cytomet-
ric analyses24. The ability of Polyman26 to bind to the cell lines harbouring the wild type or the mutated DC-SIGN 
was assessed by fluorescence microscopy; untrasfected CHO cells were used as a negative control. Despite the 
overall low fluorescence of Polyman26 stain (especially after the subtraction of the signal due to the cellular 
autofluorescence, induced by experimental conditions), cell images shown in Fig. 2 demonstrate that Polyman26 
Figure 1. Polyman26. Structure of the polyvalent dendrimer Polyman26.
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binds to DC-SIGN-wt and Δ Rep, but not to the Δ CRD mutant. These results indicate that the lack of CRD 
prevents the interaction between Polyman26 and DC-SIGN, thus demonstrating that this highly mannosylated 
dendrimer selectively binds to the carbohydrate recognition domain of the protein (Fig. 2).
Polyman26 internalization. To study Polyman26 internalization, human immature Monocyte 
Derived Dendritic Cells (iMDDCs) were used as a model. iMDDCs were treated with Polyman26 for differ-
ent time intervals and at different temperatures. After a washing step, DiD’ oil (1,1′ -Dioctadecyl-3,3,3′ ,3′ - 
Tetramethylindodicarbocyanine Perchlorate) was used as a marker for the cellular membrane, allowing to 
dissect the dorsal membrane (i.e. cellular membrane exposed to the media) and the ventral one (i.e. cellular 
membrane in contact with the culture plate) with respect to the middle of the cell body. Pulse-chase experi-
ments were performed, and confocal images were obtained after Polyman26 removal. For each sample, opti-
cal slices were recorded, imaging both external membrane and cross/central sections. iMDDCs with labelled 
membrane (pseudo-colored in red) and treated with Polyman26 (pseudo-colored in green) are presented in 
Supplementary Fig. S3 and in Fig. 3. Remarkably, Polyman26 was already internalized after 10 min of incubation 
at 37 °C (Supplementary Fig. S3a) and was still detectable inside the cells after a 60 minute incubation (Fig. 3b and 
Supplementary Fig. S3b, where a greater number of cells is shown). A series of optical z-sections was collected; the 
absence of Polyman26 on both the dorsal and the ventral membrane and its presence in the cross section confirms 
that the internalization of the dendrimer did occur (Fig. 3 and Supplementary Fig. S3b). Importantly, Polyman26 
was not internalized when iDCs were incubated with the compound at 4 °C (Fig. 3c). Since incubation of cells 
at 4 °C has been described as a method to inhibit the energy-dependent internalization25,26, this result indicates 
that Polyman26 internalization is mediated by active mechanisms, possibly a receptor-mediated one. The lack 
of Polyman26 stain on cellular membrane can be ascribed to the multiple washing steps and to its intrinsic low 
fluorescence, which prevents observing its stain when not concentrated within cellular organelles.
Polyman26 localization within Dendritic Cells. To study the internalization route of Polyman26 in 
iMDDCs and its localization in intracellular compartments, fluorescent Ovalbumin (OVA 488), Transferrin (633) 
and Lysotracker Red (577) were used. Transferrin27 is known to be internalized by cells and routed to early endo-
somes compartments. DCs internalize large quantities of OVA by Mannose Receptor (MR)-mediated endocytosis 
and small quantities by pinocytosis. While pinocytosed OVA is transported towards lysosomes, MR-endocytosed 
OVA colocalize with Early Endosome Antigen 1 (EEA1) positive endosomes for up to six hours after antigen 
uptake28. Therefore, once labelled with fluorescent dyes, they can be used to visualize these specific organelles. 
LysoTracker Red is a red-fluorescent dye for labelling and tracking acidic organelles in live cells, therefore it is 
selective for late endosomes and lysosomes.
Notably, antibodies could not be used to label cellular organelles because after the permeabilization procedure, 
required to allow antibodies to enter into the cell, and the washing steps, Polyman26 could not any longer be 
detected in the cells (not shown).
Confocal imaging was used to determine the degree of colocalization between Polyman26 and fluorescent 
tracers. After removal of unbound Polyman26, images were taken on live cells at different time intervals.
Figure 2. Specificity control of DC-SIGN binding to Polyman26 (pseudo-colored in green). Cells were 
incubated with Polyman26 for 30 min at RT; after a washing step, pictures of live cells were taken using an 
epifluorescence microscope. Both the bright field (left) and the signal of Polyman26 (right) are shown.  
(a) Untransfected CHO (Negative control); (b) CHO cells expressing DC-SIGN-wt; (c) CHO cells expressing 
DC-SIGN-Δ CRD; (d) CHO cells expressing DC-SIGN-Δ Rep.
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Figure 4 shows selected iMDDCs presenting Polyman26 stain (pseudo-colored in green) superimposed to 
the fluorescent tracer (pseudo-colored in red), for each tracer at different time points. Experiments with OVA 
and Transferrin were performed simultaneously, observing the two tracers at two different wavelengths on the 
same cells. Colocalization results in yellow spots. Both the colocalization of Polyman26 and OVA (Figs 4a and 5a) 
and Polyman26 and Transferrin (Figs 4b and 5b) gradually increased in time, peaking after 20 min of chase; the 
subsequent decrease of colocalization could indicate that Polyman26 and the tracers follow different endocytic 
routes (see also Supplementary Fig. S4). The highest degree of colocalization was obtained between Polyman26 
and LysoTracker, reaching coefficient values > 0.7 (Figs 4c and 5c). Polyman26 reached lysosomes already after 
30 min of incubation, and the colocalization value was close to the one obtained after 120 min of incubation (0.8 vs 
0.7, Fig. 5c).
Modulation of innate immune Responses by Polyman26. Polyman26 binds DC-SIGN selectively via 
CRD; we thus evaluated the ability of the compound to activate innate immune responses. Due to the difficulty 
in isolating mucosal immature DCs from tissues, human iMDDCs were used in the experiments as a model21,29. 
Upon ligand binding, DC-SIGN activates signaling pathways that modulate Toll-like Receptor (TLR) signaling, 
Figure 3. Polyman26 pulse-chase internalization experiments. Optical slices of iMDDCs incubated with 50 μ 
M Polyman26 (pseudo-colored in green) in HBSS and, after 3 washes with HBSS (150 μ L), stained for 2 min at 
RT with DiD’ (pseudo-colored in red) as membrane marker. After the last washing steps (2 washes with 150 μ L 
of HBSS), cells were fixed with 1% PFA. Left: dorsal membrane (i.e. exposed to the media); centre: middle of the 
cell body; right: ventral membrane (i.e. in contact with the culture plate). (a) Negative control; (b) iMDDCs were 
incubated with 50 μ M of Polyman26 at 37 °C for 60 min; (c) iDCs were incubated with 50 μ M of Polyman26 at 4 °C 
for 20 min.
www.nature.com/scientificreports/
5Scientific RepoRts | 6:35373 | DOI: 10.1038/srep35373
but can also trigger innate immune responses independently of TLR activation30. Experiments performed showed 
that Polyman26 inhibit HIV trans infection in a clearly dose-dependent way23 and binds to DC-SIGN, as shown 
by direct interaction SPR studies with immobilized DC-SIGN Extracellular Domain (Fieschi F., Bernardi A. et al.; 
unpublished). As 10 μ M was the minimum concentration of Polyman26 that completely inhibited HIV trans 
infection, we selected this concentration for functional experiments. Thus, iMDDCs were exposed to Polyman26 
(10 μ M) or medium culture alone (unstimulated control) in the presence/absence of Lipopolysaccharide (LPS; 
1 μ g/ml), an agonist of TLR4. The expression of cytokines, chemokines, and genes involved in DC activation and 
maturation was assessed using a Real Time PCR array specific for Dendritic and Antigen Presenting Cells. The 
production of cytokines and chemokines in the supernatants of iMDDCs cultures was analyzed by ELISA.
Results indicated that exposure of iMMDCs to Polyman26 up-regulated the expression of the β chemokines 
CCL3 and CCL4 (MIP-1α and MIP-1β ) compared to untreated controls; an additive effect was observed upon 
simultaneous treatment with Polyman26 and LPS (Fig. 6a). CCL3 and CCL4 secretion in the iMDDC super-
natants was significantly up-regulated as well, both at 24 and 48 h (Fig. 6b,c). The expression of CCL7 (MCP3) 
was also increased by the dendrimer both in the presence and in the absence of LPS, albeit to a lesser extent. 
The mRNA and protein levels of CCL5 (RANTES) were significantly up-regulated upon co-administration of 
Polyman26 and LPS, whereas they were only modestly increased by Polyman26 alone (Fig. 6a,d). Interestingly, 
the expression of the HIV-1 co-receptors CCR5 and CXCR4, as well as that of DC-SIGN itself, was not modulated 
by Polyman26 either alone or when in association with LPS (not shown). In contrast, the dendrimer decreased the 
expression of the chemokine receptor CCR1 (Chemokine (C-C Motif) Receptor 1) (Fig. 6).
Exposure to Polyman26 also resulted in the up-regulation of the pro-inflammatory cytokines IL-1β , IL-6, and 
TNFα . In particular, the expression and the protein production of IL-1β and TNFα were strongly increased by the 
compound. Also in this case, co-treatment with LPS potentiated this effect in an additive way (Fig. 7a,b,d). IL-6 
Figure 4. Subcellular localization of Polyman26 after internalization. Images were taken with a confocal 
microscope on live cells, at the time intervals indicated in the panels. Polyman26 is pseudo-colored in green and 
the tracers are pseudo-colored in red. (a) iMDDCs were incubated with Polyman26 (50 μ M) plus OVA 488 in 
HBSS, for 10 min at RT and analysed after a washing step at indicated time points. (b) iMDDCs were incubated 
with Polyman26 (50 μ M) plus Transferrin 633 in HBSS, for 10 min at RT and analysed after a washing step at 
indicated time points. (c) iMDDCs were incubated with 100 μ M Polyman26 in HBSS for 20 min at RT (left) or 
120 min at 37 °C (right); after a washing step, LysoTracker was added and cells were analysed.
www.nature.com/scientificreports/
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was up-regulated as well upon treatment with both Polyman26 and Polyman26 plus LPS, even though to a lesser 
degree than IL-1β and TNFα (Fig. 7a,c).
Furthermore, Polyman26, both alone and in combination with LPS, augmented the expression of both the 
IL-12 subunits (p35 and p40) (Fig. 7a) and significantly increased the concentration of IL-12 in iMDDCs super-
natants both at 24 and 48 h (Fig. 7e). Interestingly, an up-regulation of the transcription factor interferon regula-
tory factor 8 (IRF8), which is involved in the regulation of IL-12 expression, was observed as well. The compound 
also increased the expression levels of the Th1 cytokine IFNγ . Finally, Polyman26 induced the expression of TLR9 
and CD40 Ligand (CD40 L) (Fig. 7a).
Further analysis showed that Polyman26 modulated the expression of cytokine and receptors involved in DC 
differentiation, maturation, and homeostasis (Fig. 8). Thus, Polyman26 strongly increased the expression and 
the production of Granulocyte-macrophage Colony-stimulating Factor (GM-CSF), a cytokine critical for DC 
differentiation and maturation; also in this case, an additive effect was observed upon combined treatment with 
Polyman26 and LPS (Fig. 8a,b). On the contrary, Polyman26 decreased the expression of MCSFR, the receptor of 
Macrophage Colony-Stimulating Factor (MCSF), a cytokine which exerts an inhibitory effect on DCs differenti-
ation. Finally, Polyman26 augmented the expression of Fms-Related Tyrosine Kinase 3 (Flt3), Flt3 ligand (Flt3L), 
and TNSF11, proteins that promote DC development, survival, and activation.
Evaluation of Polyman26 toxicity. We have previously demonstrated that Polyman26 is not toxic towards 
a DC-SIGN-expressing cell line (B-THP1/DC-SIGN cells)23. To exclude potential toxic effects on iMDCCs, the 
cells were incubated with increasing concentrations of Polyman26, and then labelled with 7-Amino-Actinomycin 
D (7-AAD), which identifies non-viable cells. Exposure to the dendrimer for 3, 24, or 48 hours did not alter signif-
icantly the viability of iMDDCs up to a concentration of 100 μ M (Supplementary Fig. S5).
Discussion
Mucosal DCs, which express DC-SIGN at high levels, are among the first cell types to encounter pathogens 
and play a central role in the induction and modulation of the adaptive immunity. Upon ligand binding, 
DC-SIGN not only acts as uptake receptor but can also initiate or modulate immune responses. These features 
make DC-SIGN an ideal target for the development of vaccines and immunomodulants. Strategies to target 
Figure 5. Percentage of colocalization. Pearson’s correlation coefficient (PCC) plot representing the 
colocalization between Polyman26 and (a) OVA 488, (b) Transferrin 633, (c) LysoTracker 577. Values represent 
the mean ± SD.
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DC-SIGN include carbohydrate ligands and specific monoclonal antibodies. Carbohydrate DC-SIGN ligands 
are less toxic and immunogenic than anti-DC-SIGN monoclonal antibodies, even though they can be less 
specific15,31.
Figure 6. Expression of chemokine and chemokine receptors following Polyman26 stimulation. iMDDCs 
from 4 separate donors were treated with medium culture, Polyman26 (10 μ M), LPS (1 μ g/ml), or Polyman26+ 
LPS for 3, 24, and 48 h. (a) Gene expression following 3 h treatment. For each condition, cDNA was pooled 
and gene expression evaluated by Real-time PCR array. Expression was shown as fold induction relative to 
unstimulated control. Targets showing at least a 2-fold modulation were considered significant. (b–d) β chemokine 
production. The concentration of CCL3 (b), CCL4 (c), and CCL5 (d) in the culture supernatants was assayed by 
ELISA at 24 and 48 h. (b-d) Values represent the mean ± SD. *p < 0.05; **p < 0.01 (Student’s t-test).
www.nature.com/scientificreports/
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Figure 7. Expression of cytokines and innate immunity receptors following Polyman26 stimulation. 
iMDDCs from 4 separate donors were treated with medium culture, Polyman26 (10 μ M), LPS (1 μ g/ml), or 
Polyman26+ LPS for 3, 24, and 48 h. (a) Gene expression following 3 h treatment. For each condition, cDNA 
was pooled and gene expression evaluated by Real-time PCR array. Expression was shown as fold induction 
relative to unstimulated control. Targets showing at least a 2-fold modulation were considered significant. 
(b–e) Cytokine production. The concentration of Il-1β (b), IL-6 (c), TNFα , (d), and IL-12 (e) in the culture 
supernatants was assayed by ELISA at 24 and 48 h. (b-e) Values represent the mean ± SD. *p < 0.05; **p < 0.01 
(Student’s t-test).
www.nature.com/scientificreports/
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We recently demonstrated that the glycomimetic compound Polyman26, a hexavalent dendrimer composed 
of two trivalent dendrons connected by a rod-like spacer, completely inhibits HIV-1 Bal Trans infection of CD4 T 
cells at a concentration of 10 μ M and results in an inhibition of infection > 98% at a concentration of 0.5 μ M with 
an IC50 of 24 nM23.
Epithelia are effective barriers to absorption of large hydrophilic molecules. For instance, the permeability of 
vaginal epithelium to particles and molecules greater than 30 nm is limited32. However, the size of Polyman26 is cer-
tainly below that threshold. Indeed, a hydrodynamic radius of 1.3 nm was determined by Dynamic Light Scattering 
experiments33. Thus, the dendrimer could cross the epithelium, diffuse into intact mucosal tissue, and reach resident 
DCs. Furthermore, Polyman26 is endowed with amphiphilic properties33 that facilitate penetration into the sube-
pithelial layer of the mucosa, and its absorption in vivo might be further improved with an adequate formulation.
The natural fluorescence of Polyman26 allowed us to study its interaction with specific DC-SIGN subdomains 
and to monitor its internalization pathway. Due to its suboptimal intrinsic fluorescence, Polyman26 was used 
at a concentration ranging from 50 to 100 μ M (i.e. 5–10 times more than the concentration at which it com-
pletely inhibits HIV trans infection). This is a clear limitation of the system, which, however, allows to observe the 
behaviour of the ligand (Polyman26) in the absence of additional fluorophoric elements, which could modify its 
functional interaction with the cell. For instance, the label of ligands with fluorescent dyes could affect their prop-
erties, at least in terms of toxicity and binding. We therefore believe that the data, despite having been obtained 
with a sub-optimal chromophore, are of interest because they reflect the unbiased behaviour of the ligand in 
the interaction and internalization process. Results obtained by fluorescence and confocal microscopy indicate 
that Polyman26 specifically interacts with DC-SIGN CRD and is internalized via receptor mediated endocytosis. 
DC-SIGN mediates the internalization and routing of its ligands to the endolysosomal pathway, which results in 
peptides being presented by MHC class II molecules. Antigens targeted to DC-SIGN were nevertheless reported 
to be presented to CD8 T lymphocytes suggesting the existence of a still undefined mechanism of cross pres-
entation by MHC class I molecules14,15. Our results indicate that Polyman26 ends up in lysosomes. Nevertheless, 
it also transits through the early endosomes, and resides there for a quite prolonged period, as shown by the 
colocalization with OVA and Transferrin. Since early endosomes play an important role in the cross-presentation 
on MHC class I, this result has important implications for the development of vaccines able to induce cytotoxic 
T-lymphocyte (CTL) responses.
Figure 8. Expression of homeostatic cytokines and receptors. iMDDCs from 4 separate donors were treated 
with medium culture, Polyman26 (10 μ M), LPS (1 μ g/ml), or Polyman26+ LPS for 3, 24, and 48 h. (a) Gene 
expression following 3 h treatment. For each condition, cDNA was pooled and gene expression evaluated by 
Real-time PCR array. Expression was normalized to 5 housekeeping genes and shown as fold induction relative 
to unstimulated control. Targets showing at least a 2-fold modulation were considered significant. (b) The 
concentration of GM-CSF in the culture supernatants was assayed by ELISA at 24 and 48 h. Values represent the 
mean ± SD. *p < 0.05; **p < 0.01 (Student’s t-test).
www.nature.com/scientificreports/
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As DC-SIGN can activate intracellular signaling with different outcomes depending on the ligand involved, 
we evaluated if Polyman26 could induce the activation of innate immune responses.
Results show that Polyman26, alone and in combination with LPS, induces the production of the β chemok-
ines CCL3, CCL4, and CCL5, which are the endogenous ligands of the HIV co-receptor CCR5 and can prevent 
the infection by HIV-1 R5 tropic strain34. Thus, Polyman26, by enhancing the expression of these β chemokines, 
could hamper HIV infection of CCR5 expressing CD4 T lymphocytes, macrophages and DCs in genital mucosae.
Besides modulating β chemokines, Polyman26 induced an increase in the production of the proinflammatory 
cytokines IL-1β , IL-6, and TNFα . These results can be relevant considering that pro-inflammatory cytokines 
not only induce local responses that help to contain infections but also enhance the expansion and the functions 
of T lymphocytes. Moreover, TNFα also promotes the migration of DCs to the lymph nodes and their matura-
tion35,36. A significant upregulation of IL-12 and IFNγ by Polyman26 was observed as well. Because both IL-12 
and IFNγ skew immune responses toward the Th1 phenotype, these results suggest that Polyman26 has the ability 
to polarize adaptive immune responses toward such phenotype, thus promoting cell-mediated immunity against 
pathogens. In this context it is important to underline that local IFNγ production by DCs contributes to the early 
host defenses against infections and mediates autocrine and paracrine activation of Antigen Presenting Cells37.
Interestingly, Polyman26 also modulates receptors and cytokines involved in DC maturation, homeostasis, 
and activation. Indeed, Polyman26 significantly up-regulates GM-CSF, a cytokine that promotes DC differenti-
ation and maturation. In addition, Polyman26 increases the expression of Flt3 and Flt3L, both required for the 
homeostatic DC development in the periphery38, as well as the expression of TNSF11, which acts as a DC sur-
vival factor and augments the ability of DCs to stimulate the proliferation of naïve T lymphocytes39. Conversely, 
Polyman26 reduces the expression of CCR1, a chemokine receptor down-regulated during DC maturation40,41, 
and the receptor of MCSF, a cytokine which impairs DC differentiation42. Finally, Polyman26 upregulates TLR9, 
and CD40L, whose expression by DCs can regulate B cell functions and the production of IgA and IgG43.
We previously reported that Polyman19, a glycodendrimer with a different type of core, induced the expres-
sion of chemokines and innate immunity cytokines21. However, a direct comparison between the effects of 
Polyman19 and Polyman26 on cytokine and chemokine expression cannot be drawn. Indeed, the experiments 
have been performed on different groups of healthy donors using different techniques and experimental set-
tings. All these caveats notwithstanding, we observed that Polyman19 stimulation results in a more pronounced 
upregulation of the β Chemokines CCL3, CCL4 and CCL5, and of cytokines IL-1β , IL-6 and TNFα compared to 
Polyman26 stimulation. Nevertheless, it has to be noticed that an excessive production of cytokines and chemok-
ines may cause detrimental inflammatory responses and tissue damage. Further studies in both ex vivo models 
(i.e human cervico-vaginal explants) and in vivo models (i.e. humanized mice or primates) will be necessary to 
evaluate if the levels of cytokines and chemokines induced by Polyman26 are adequate to exert immunomodula-
tory and adjuvant effects in vivo.
Cytotoxicity experiments demonstrated that Polyman26 does not exert toxic effects towards DC-SIGN 
expressing cell lines23 and iMDDCs. Nonetheless, further experiments on human tissue models (e.g. 
cervico-vaginal explants) should be performed to exclude potential toxic effects of Polyman26 on primary epi-
thelial and immune cells of the mucosa and to rule out eventual damages to overall tissue integrity. Experiments 
on animal models will also be necessary to exclude long-term toxicity and possible toxic effects of the compound 
caused by the activation of the immune system.
Our findings suggest that Polyman26 may confer peculiar advantages for the prevention and the treatment of 
infections. As Polyman26 activates multiple effectors of the innate immunity and tailors the adaptive responses 
towards a Th-1 phenotype, it could offer protection against a broad range of pathogens. Furthermore, Polyman26 
may potentiate the natural defenses of the host rather than targeting the pathogen, thus avoiding the development 
of microbial resistances. Immunomodulatory therapies could have side effects due to a generalized activation of 
the immune system. However, Polyman26 specifically targets DC-SIGN-expressing myeloid DCs, thus reducing 
the risk of side effects, especially in the case of topical administration. Further studies in the appropriate animal 
model (i.e. humanized mice or primates) will be necessary to validate these data and to better elucidate the effects 
of Polyman26 on the immune system.
Results herein show that Polyman26 is efficiently internalized by DCs via receptor-mediated endocytosis and 
then is routed to early endosomal and endolysosomal compartments; which has implication for the development 
of delivering systems that target specifically DCs and facilitate antigen presentation on MHC I and MHC II mol-
ecules. Furthermore, Polyman26 up-regulates multiple effectors of the innate immunity, including chemokines, 
cytokines, and receptors with important roles in the antiviral responses, in the induction of a Th1 response, and 
in the regulation of DC survival, maturation and activation. These results thus suggest the intriguing possibility 
of exploiting polyvalent carbohydrate ligands of DC-SIGN in the design of novel immunomodulants and vaccine 
adjuvants. Notably, as DC-SIGN is expressed by mucosal DCs, these glycomimetic compounds might specifically 
be used to manipulate the immune response with the aim of increasing mucosal protection against pathogens.
Materials and Methods
Synthesis and characterization of Polyman26. The synthesis and the characterization of Polyman26 
were previously reported23,33. To exclude LPS contamination of Polyman26, Limulus Amebocyte Lysate (LAL) 
assay (Hycult Biotec, Netherlands) was performed. LPS content of Polyman26 at 10 μ M (the concentration used 
to study the immunomodulatory effects of Polyman26) was below the detection limit of the assay (0.04 EU/ml).
Cell culture. Transfection of CHO cells. CHO cell lines stably expressing DC-SIGN-wt, DC-SIGN-Δ CRD 
or DC-SIGN-Δ Rep were established by LipofectamineTM 2000 (Life Technologies Invitrogen, Bleiswijk, The 
Netherlands) transfection24.
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Differentiation of immature DCs from Monocytes. Human immature DCs were differentiated from Monocytes 
as previously described19,21. All experimental protocols were approved by the Institutional Review Boards of 
Radboud University Medical Center (Netherlands) and Vimercate Hospital (Italy). Peripheral Blood Mononuclear 
Cells (PBMCs) were isolated from buffy coats (Sanquin) obtained from healthy volunteers after written informed 
consent and all methods were carried out in accordance with the approved guidelines. Briefly, monocytes were 
purified from Peripheral Blood Mononuclear Cells (PBMCs) using the anti-human CD14 MicroBeads (Miltenyi 
Biotech, Calderara di Reno, Italy). Monocytes were differentiated into iMDDCs with hIL-4 and hGM-CSF (both 
20 ng/ml; R&D Systems, Minneapolis, USA) for 6 days.
Binding Assays between Polyman26 and DC-SIGN expressed in CHO cells. CHO cells plated 
on a 96-well plate were incubated with 100 μ M Polyman26 in HBSS for 30 min at RT. After thorough washing 
with HBSS, live cells were observed using a commercial Leica DMI6000 epi fluorescence microscope with AFC 
equipped with a 63× oil immersion objective (HC PL APO 63x/1.40–0.60 OIL, Leica Microsystems) and filter 
system DAPI ET (BP 350/50, LP 400, BP 460/50), GFP ET (BP 470/40, LP 495, BP 524/50), DsRed ET (BP 546/11, 
LP 560, BP 605/75) and Y5 ET (BP 620/60, LP 660, BP 700/75). Polyman26 was excited at 340–380 nm. The ability 
of Polyman26 to bind to the different cell lines was assessed qualitatively by comparing the residual cellular fluo-
rescence with the negative control. Images were analyzed using Fiji software.
Polyman26 internalization in Immature Dendritic Cells. Human iMDDCs were allowed attach-
ing to a Labtek 8-chamber slides in serum free RPMI medium. Cells were incubated with 50 μ M Polyman26 in 
HBSS either at 37 °C for 10 or 60 min or at 4 °C for 20 min and then washed with HBSS (3 washes with 150 μ L of 
HBSS). Cells were incubated with 100 μ L of DiD’ oil (1,1′ -Dioctadecyl-3,3,3′ ,3′ -Tetramethylindodicarbocyanine 
Perchlorate, InvitrogenTM, 9 μ M) for 2 min at RT. After a washing step (2 washes with 150 μ L of HBSS), cells 
incubated with Polyman26 at 37 °C for 10 min were observed alive. Cells incubated with Polyman26 at 37 °C 
for 60 min or 4 °C for 20 min were fixed with 1% paraformaldehyde for 20 min at RT, washed and blocked with 
100 mM glycine in TBS (Tris-buffered saline) for 10 min at RT. Confocal images were obtained in a sequential 
manner using a commercial Leica SP8 SMD-WLL (Leica Microsystems) confocal microscope equipped with a 
PMT and Hybrid detectors (HyD) and a 63× water immersion objective (HC PL APO 63x/1.2 W motCORR CS2, 
Leica Microsystems). Polyman26 was excited at 405 nm. Images were analyzed using Fiji software.
Colocalization experiments. Human iMDDCs were allowed to attach to a labtek 8 well chamber slides in 
serum free medium. Cells were incubated with an HBSS solution of 50 μ M Polyman26 (100 μ L) containing fluo-
rescent Ovalbumin (OVA, Ovalbumin, Alexa Fluor® 488 Conjugate, ThermoFisher Scientific, The Netherlands, 
20 μ g mL−1) or fluorescent Transferrin (Transferrin From Human Serum, Alexa Fluor® 633 Conjugate, 
ThermoFisher Scientific, The Netherlands, 20 μ g mL−1) for 10 min at RT, then a washing step was performed. In 
parallel, cells were incubated with an HBSS solution of 100 μ M Polyman26 (100 μ L) for 20 min at RT or 2 hours at 
37 °C; after a washing step, 200 μ L of LysoTracker Red (ThermoFisher Scientific, The Netherlands, 0.1 μ M) were 
added. Live cells were analyzed with a commercial Leica SP8 SMD-WLL (Leica Microsystems) confocal micro-
scope equipped with PMT and Hybrid detectors (HyD) and a 63× water immersion objective (HC PL APO 63× 
/1.2 W motCORR CS2, Leica Microsystems). Polyman26 was excited at 405 nm; OVA 488 at 488 nm, Transferrin 
633 at 633 nm and LysoTracker Red at 577 nm. Images were taken at different time intervals to follow the intracel-
lular localization of Polyman26 and fluorescent tracers. Images were analyzed using Fiji software. The degree of 
colocalization between Polyman26 and the tracers was calculated through Pearson’s correlation coefficients. The 
JACoP plugin of the Fiji software was used44.
Microscopy equipment and settings. Images 203.44 × 151.96 micron2 were acquired with a resolution of 
6.8421 pixels per micron (Leica DMI6000 epi fluorescence microscope, Fig. 2). Images 106.66 × 106.66 micron2 
were acquired with a resolution of 9.6005 pixels per micron (Leica SP8 SMD-WLL confocal microscope, Figs 3 
and 4). Images depth is 16 bits per pixel (Figs 2 and 4c) or 8 bits per pixel (Figs 3 and 4a,b). Magnification is 0.5.
RNA Extraction and cDNA synthesis. RNA was extracted from iMDDCs using RNA-bee Reagent 
(Tel-Test Inc, Friendswood, TX, USA). To remove contaminant DNA, RNA was treated with RNase-free DNase 
I (New Englands Biolabs, Ipswich, MA, USA). cDNA was synthesized using Moloney murine leukemia virus 
(M-MLV) reverse transcriptase, in the presence of random hexamer primers, oligo DT, and RNase inhibitor (all 
from Promega, Milan, Italia).
Real Time PCR. The gene expression profile upon iMDDCs stimulation with Polyman26 in the presence/
absence of LPS was analyzed using the Human Dendritic and Antigen Presenting Cell RT2 Profiler™ PCR Array 
(SABioscience; Qiagen, Milan, Italy), which includes a panel of 84 genes related to DCs maturation and activa-
tion plus 5 housekeeping genes on 96-well plates. Reactions were performed using the iTaq™ Universal SYBR® 
Green supermix on the real-time PCR detection system CFX Connect™ (Biorad, Milano, Italy). The results were 
analyzed exploiting the web resource GeneGlobe Data Analysis Center (Qiagen). The results were normalized to 
five housekeeping genes, and the relative changes in gene expression were calculated using the Δ Δ Ct method. 
Targets showing at least a 2-fold modulation were considered significant.
ELISA. Cytokine and chemokine production in the supernatants of iMDDCs was evaluated using commercial 
ELISA kits following manufacturer’s instructions. The concentration of CCL3, CCL4, CCL5, IL1-β and IL-12 was 
measured using DuoSet kits (R&D Systems). The concentration of IL-6, TNFα , and GM-CSF was measured using 
Kit ELISA-Ready-Set-GO!® (Affimetrix eBioscience, San Diego, CA, USA).
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Evaluation of Polyman26 toxicity. DC-SIGN expression by iMDDCs was checked by staining with the 
anti-human DC-SIGN PE antibody (clone AZND1, Beckman Coulter, Milano, Italy). To evaluate Polyman26 
toxicity, iMMDCs were incubated with increasing concentration of Polyman26 for 3, 24, and 48 hours, and then 
labeled with 7-aminoactinomycin D (7-AAD) (Beckman Coulter). Samples were acquired by using a Gallios™ 
Flow Cytometer and data were analysed with Kaluza® Flow Analysis Software (both Beckman Coulter).
Statistic. Comparisons between the different treatments were performed using unpaired Student’s T Test for 
unequal variances with a two tailed P value. Significance was set at P < 0.05. Statistical analysis was performed 
using GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA).
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